Feb. 20, 2018
- Colborn LK. Office of Access Management. Mayo Clinic, Rochester, Minn. Jan. 28, 2016.
- Translational Research Program. National Cancer Institute. http://trp.cancer.gov/default.htm. Accessed March 17, 2016.
- NCI-designated cancer centers. National Cancer Institute. http://www.cancer.gov/research/nci-role/cancer-centers. Accessed April 22, 2016.
- Mayo Clinic Cancer Center. National Cancer Institute. http://www.cancer.gov/research/nci-role/cancer-centers/find/mayoclinic. Accessed April 22, 2016.
- Cancer Center of Excellence designation. Florida Department of Health. http://www.floridahealth.gov/provider-and-partner-resources/research/cancer-center-of-excellence-award.html. Accessed April 22, 2016.
A continuación se enumeran ensayos clínicos actuales.400 estudios en Hematología
(estudios abiertos únicamente).
Filtrar esta lista de estudios según la ubicación, el estado del estudio y más.
The primary purpose of this study is to generate pediatric-specific reference ranges that take into account patient sex, age, corrected gestational age, ethnicity, etc., and laboratory variables for various coagulation studies.
Scottsdale/Phoenix, Ariz., Rochester, Minn.
This is a phase I, multicenter, open-label, dose-escalation study of BFCR4350A administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM).
The purpose of this study is to create a long-term, prospective database of cutaneous lymphoma that will lead to a better understanding of the biological behavior of cutaneous lymphomas as well as the effectiveness of interventions.
Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.
This is a multicenter, multicountry, open-label, Phase 1b/2a dose-escalation study to determine the maximum tolerated dose of CC-220 when administered as monotherapy and in combination with dexamethasone. The study will consist of an escalating dose-escalation portion (Part 1) as well as an expansion of each cohort (ie, Cohort C: Monotherapy (MonoT) and Cohort D: Combination treatment with 2 drugs (DoubleT) at the recommended Phase 2 dose (RP2D) to further evaluate safety and estimate preliminary efficacy (Part 2).
This phase II trial studies how well ibrutinib with or without bortezomib and dexamethasone works in treating patients with immunoglobulin light chain amyloidosis that has come back after a period of improvement or that does not respond to treatment. Ibrutinib and bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ibrutinib with or without bortezomib and dexamethasone may work better in treating patients with relapsed or refractory immunoglobulin light chain amyloidosis.
Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz.
The pupose of this study is to assess the safety and tolerability of APG-2575 when orally administered to patients with hematologic malignancies.
Scottsdale/Phoenix, Ariz., Rochester, Minn., Mankato, Minn., La Crosse, Wis., Eau Claire, Wis.
The purpose of this trial is to evaluate how well ibrutinib and obinutuzumab with or without venetoclax work in treating patients with chronic lymphocytic leukemia. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ibrutinib, obinutuzumab and venetoclax may work better in treating patients with chronic lymphocytic leukemia.
Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.
This is a Phase III, multicenter, double-blind, randomized study of pracinostat vs. placebo with azacitidine (AZA) as background therapy in patients ≥ 18 years of age with newly diagnosed acute myeloid leukemia (AML), excluding acute promyelocytic leukemia and cytogenetic low-risk AML, who are unfit to receive intensive remission induction chemotherapy due to age ≥ 75 years or comorbidities. Patients will be randomized in a 1:1 ratio to one of two groups: Group A (experimental group) to receive pracinostat plus AZA and Group B (control group) to receive placebo plus AZA. Randomization will be stratified by cytogenetic risk category (intermediate vs. unfavorable-risk, according to SWOG Cytogenetic Risk Category Definitions) and ECOG performance status (0-1 vs. 2). Treatments will be administered based on 28-day cycles, with pracinostat/placebo administered orally once every other day, 3 times a week for 3 weeks, followed by one week of no treatment and AZA administered for 7 days of each cycle. Study treatment should continue until there is documented disease progression, relapse from complete remission (CR), or non-manageable toxicity. A minimum of 6 cycles may be required to achieve a complete remission. Once permanently discontinued from study treatment, patients will enter the Long-term Follow-up phase of the study and will be followed for assessment of disease progression, if applicable, and survival every 3 months (±1 month) until death. The end of this study is defined when 390 events (deaths) have occurred and the study is unblinded for final overall survival analysis. Patients who are receiving study treatment at the end of the study may have the opportunity to continue to receive the study drugs to which they were randomized to (Post- Study Observation Period), until the Sponsor informs the Investigators of the appropriate course of action based on the study results. The Post-Study Observation Period is defined as the period starting from the end of the study for a maximum of 12 months.
Rochester, Minn., Jacksonville, Fla.
The purpose of this study is to determine the overall survival of patients treated with Vigil versus gemcitabine/docetaxel.
The primary purpose of this study is to evaluate the feasibility of offering and providing Reiki Therapy in hospitalized hematology/oncology cancer patients.